Attenuation of cisplatin-induced nephrotoxicity in rats using zerumbone

African Journal of Biotechnology

Volumn 9, Issue 28, 2010, Pages 4434-4441

  Ibrahim, Mohamed Yousif ^a   Abdul, Ahmad Bustamam Hj ^a   Ibrahim, Tengku Azmi Tengku ^a   AbdelWahab, Siddig Ibrahim ^a   Elhassan, Manal Mohamed ^a   Mohan, Syam ^a  

^a UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

Antioxidant glutathione; Cisplatin; Nephrotoxicity; Oxidative stress; Zerumbone

Indexed keywords

CISPLATIN; CORN OIL; CREATININE; DIMETHYL SULFOXIDE; GLUTATHIONE; HERBACEOUS AGENT; MALONALDEHYDE; NITROGEN; UNCLASSIFIED DRUG; UREA; ZERUMBONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DETERMINATION; DRUG INDUCED DISEASE; DRUG ISOLATION; DRUG SCREENING; FEMALE; GINGER; HISTOPATHOLOGY; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY PARENCHYMA; LIPID PEROXIDATION; NEPHROTOXICITY; NONHUMAN; QUANTITATIVE STUDY; RAT; RHIZOME; RISK REDUCTION; SCORING SYSTEM; UREA NITROGEN BLOOD LEVEL;

ANIMALIA; RATTUS; ZEA MAYS; ZINGIBER ZERUMBET;

EID: 77954970107     PISSN: 16845315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Abdul AB, Adel SA, Nirmala DT, Siddig IA, Zetty NZ, Sharin R (2008). Anticancer Activity of Natural Compound (Zerumbone) Extracted from Zingiber Zerumbet in Human HeLa Cervical Cancer Cells. Int. J. Pharmacol. 4(3): 160-168.
2. Abdul AB, Siddig IW, Johari J, Adel SA, Manal MT (2009). Combinationof zerumbone and cisplatin to treat cervical intraepithelial neoplasia in female Balb/c mice. Int. J. Gynecol. Cancer. 19(6):1004-1010.
3. Yüce A, Ateşşahin A, Çeribaşi AO, Aksakal M (2007). Ellagic Acid Prevents Cisplatin-Induced Oxidative Stress in Liver and Heart Tissue of Rats. Basic Clin. Pharmacol. Toxicol. Issue 101(5): 345-349.
4. Aggarwal BB, Shishodia S (2006). Molecular targets of dietary agents for prevention and therapy of cancer, Biochem. Pharmacol. 71: 1397-1421.
5. Ali BH, Al-Moundhri M, Tageldin M, Al-Husseini IS, Mansour MA, Nemmar A (2006). Ontogenic aspects of cisplatin-induced nephrotoxicity in rats, Food Chem. Toxicol. 46: 3355-3359.
6. Ali BH, Al-Moundhri MS (2006). Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a reviewof some recent research. Food Chem. Toxicol. 44: 1173-1183.
7. Aykac G, Uysal M, Yalcin AS, Koçak-Toker N, Sivas AO zH (1985). The effect of chronic ethanol ingestion on hepatic lipid peroxide, glutathione peroxidase and glutathione transferase in rats, Toxicology, 36: 71-76.
8. Blakley BW, Cohen JI, Doolittle ND, Muldoon LL, Campbell KC, Dickey DT (2001).Strategies for prevention of toxicity caused by platinumbased chemotherapy. Laryngoscope 112: 1997-2001.
9. Chiu NY, Chang KH (1986). Zingiberaceae. Taipei: SMC Publishing Inc.
10. Ekborn A, Lindberg A, Laurell G, Wallin I, Eksborg S, Ehrsson H (2003). Ototoxicity, nephrotoxicity and pharmacokinetics of cisplatin and its monohydrated complex in the guinea pig. Cancer, Chemother. Pharmacol. 51: 36-42.
11. Fetoni AR, Sergi B, Ferraresi A, Paludetti G, Troiani D (2004). Protective effects of alphatocopherol and tiopronin against cisplatininduced ototoxicity, Acta. Otolaryngol. 124: 421-426.
12. Hoffman A, Spetner LM, Burke M (2002). Redox-regulated mechanism may account for zerumbone's ability to suppress cancer-cell proliferation. Carcinogenesis 23: 1961-1966.
13. Hong KO, Hwang JK, Park KK, Kim SH (2005). Phosphorylation of c-Jun N-terminal Kinases (JNKs) is involved in the preventive effect of xanthorrhizol on cisplatin-induced hepatotoxicity, Arch. Toxicol. 79: 231-236.
14. Iraz M, Kalcioglu MT, Kizilay A, Karatas E (2005). Aminoguanidine prevents ototoxicity induced by cisplatin in rats, Ann. Clin. Lab. Sci. 35: 329-335.
15. Iraz M, Ozerol E, Gulec M, Tasdemir S, Idiz N, Fadillioglu E (2006). Protective effect of caffeic acid phenethyl ester (CAPE) administration on cisplatin-induced oxidative damage to kidney in rat. Cell Biochem. Funct. 24: 357-361.
16. Kalkanis JG, Whitworth C, Rybak LP (2004). Vitamin E reduces cisplatin ototoxicity. Laryngoscope, 114: 538-542.
17. Kasparkova J, Delalande O, Stros M, Elizondo-Riojas MA, Vojtiskova M, Kozelka J, Brabec V (2004). Recognition of DNA interstrand cross-link of antitumor cisplatin by HMGB1 protein. Biochemistry, 42: 1234-1244.
18. Kim SH, Hong KO, Hwang JK, Park KK (2005). Xanthorrhizol has a potential to attenuate the high dose cisplatin-induced nephrotoxicity in mice, Food. Chem. Toxicol. 43: 117-122.
19. Koc A, Duru M, Ciralik H, Akcan R, Sogut S (2005). Protective agent, erdosteine, against cisplatininduced hepatic oxidant injury in rats. Mol. Cell Biochem. 278: 79-84.
20. Leitao DJ, Blakley BW (2003). Quantification of sodium thiosulphate protection on cisplatin-induced, toxicities. J. Otolaryngol. 32: 146-50.
21. Leonetti C, Biroccio A, Gabellini C, Scarsella M, Maresca V, Flori E (2003). Alpha-tocopherol protects against cisplatin induced toxicity without interfering with antitumor efficacy, Int. J. Cancer, 104: 243-250.
22. Liu J, Liu Y, Habeebu SS, Klaassen CD (1998). Metallothionein (MT)-null mice are sensitive to cisplatin-induced hepatotoxicity, Toxicol. Appl. Pharmacol. 149: 24-31.
23. Mansour HH, Hafez HF, Fahmy NM (2006). Silymarin modulates cisplatin induced oxidative stress and hepatotoxicity in rats, J. Biochem. Mol. Biol. 39: 656-661.
24. Murakami A, Hayashi R, Takana T, Kwon KH, Ohigashi H, Safitri R (2003). Suppression of dextran sodium sulfate induced colitis in mice by zerumbone, a subtropical ginger sesquiterpene, and nimesulide: separately and in combination, Biochem. Pharmacol. 66: 1253-1261.
25. Nowak G (2002). Protein kinase C-alpha and ERK1/2 mediate mitochondrial dysfunction, decreases in active Na+ transport, and cisplatin-induced apoptosis in renal cells, J. Biol. Chem. 277: 43377-43388.
26. Rabik CA, Dolan ME (2007). Molecular Mechanisms of Resistance and Toxicity Associated. Cancer Treat. Rev. 33(1): 9-23.
27. Ramesh G, Reeves WB (2002). TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity, J. Clin. Invest. 110: 835-842.
28. Ravi RS, Somini SM, Rybak LP (1995). Mechanism of cisplatin ototoxicity. Antioxidant system, Pharmacol. Toxicol. 76: 386-394.
29. Sakinah SA, Handayani ST, Hawariah LP (2007). Zerumbone induced apoptosis in kidney cancer cells via modulation of Bax/Bcl-2 ratio. Cancer Cell Int. 7: p. 4.
30. Surh YJ (1999). Molecular mechanisms of chemopreventive effects of selected dietary and medicinal phenolic substances. Mutation Research-Fund. Mol. Mechan. Mutat. 428: 305-327.
31. Takada Y, Murakami A, Aggarwal BB (2005). Zerumbone abolishes NFjB and IjBa kinase activation leading to suppression of antiapoptotic and metastatic gene expression, upregulation of apoptosis, and down regulation of invasion. Oncogene, 24: 6957-6969.
32. Townsend DM, Hanigan MH (2002). Inhibition of gamma-glutamyl transpeptidase or cysteine Sconjugate beta-lyase activity blocks the nephrotoxicity of cisplatin in mice, J. Pharmacol. Exp. Ther. 300: 142-148.
33. Visarus TM, Putt DA, Schare JM, Pegouske DM, Lash LH (1996). Pathways of glutathione metabolism and transport in isolated proximal tubular cells from rat kidney. Biochem. Pharmacol. 52: 259-272.
34. Weijl NI, Elsendoorn TJ, Lentjes EG, Hopman GD, Wipkink-Bakker A, Zwinderman AH (2004). Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, doubleblind, placebocontrolled study, Eur. J. Cancer. 40: 1713-1723. with Platinating Agents, Cancer Treat. Rev. 33: 9-23.
35. Xiao T, Choudhary S, Zhang W, Ansari NH, Salahudeen A (2003). Possible involvement of oxidative stress in cisplatin induced apoptosis in LLC-PK1 cells, J. Toxicol. Environ. Health A. 66: 469-479.
36. Yao X, Panichpisal K, Kurtzman N, Nugent K (2007). Cisplatin nephrotoxicity: a review. Am. J. Med. Sci. 334: 115-124.
37. Yingjun L, Xiuqiang L, Chunwei L, Gexin L, Yaping J, Hao T (2008). Selection of agents for prevention of cisplatin-induced hepatotoxicity, Pharmacol. Res. 57: 125-131.